Clinical studies recruiting near Cape Girardeau

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
NA · Mercy Cancer Center - Cape Girardeau · Alliance for Clinical Trials in Oncology · NCT07091617 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · Mercy Cancer Center - Cape Girardeau · NRG Oncology · NCT05174169 Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Canc
Phase 3 · Mercy Cancer Center - Cape Girardeau · Alliance for Clinical Trials in Oncology · NCT06632327 ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · Mercy Cancer Center - Cape Girardeau · Alliance for Clinical Trials in Oncology · NCT06876714 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · Mercy Cancer Center - Cape Girardeau · National Cancer Institute (NCI) · NCT04269902 Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Phase N/A · Mercy Cancer Center - Cape Girardeau · Alliance for Clinical Trials in Oncology · NCT04242095 Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 · Mercy Cancer Center - Cape Girardeau · ECOG-ACRIN Cancer Research Group · NCT04566328 mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · Mercy Cancer Center - Cape Girardeau · Alliance for Clinical Trials in Oncology · NCT05677490 Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NA · Mercy Cancer Center - Cape Girardeau · NRG Oncology · NCT05080673 Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Phase N/A · Mercy Cancer Center - Cape Girardeau · ECOG-ACRIN Cancer Research Group · NCT04239573 Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Phase 3 · Mercy Cancer Center - Cape Girardeau · Children's Oncology Group · NCT06513962 Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Phase 2 · Mercy Cancer Center - Cape Girardeau · SWOG Cancer Research Network · NCT04205968 Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Phase 3 · Mercy Cancer Center - Cape Girardeau · ECOG-ACRIN Cancer Research Group · NCT04423211 Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head
Phase 2 · Mercy Cancer Center - Cape Girardeau · ECOG-ACRIN Cancer Research Group · NCT02734537 Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
NA · Mercy Cancer Center - Cape Girardeau · Alliance for Clinical Trials in Oncology · NCT07283939 Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Phase 3 · Mercy Cancer Center - Cape Girardeau · ECOG-ACRIN Cancer Research Group · NCT06475989 Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabo
Phase 2 · Mercy Cancer Center - Cape Girardeau · National Cancer Institute (NCI) · NCT03866382 Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung
Phase 3 · Mercy Cancer Center - Cape Girardeau · National Cancer Institute (NCI) · NCT04267848 Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Phase 3 · Mercy Cancer Center - Cape Girardeau · ECOG-ACRIN Cancer Research Group · NCT03937635 Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Phase 2/Phase 3 · Mercy Cancer Center - Cape Girardeau · SWOG Cancer Research Network · NCT03851445 Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Phase 3 · Mercy Cancer Center - Cape Girardeau · NRG Oncology · NCT06580314 Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · Mercy Cancer Center - Cape Girardeau · National Cancer Institute (NCI) · NCT04181060 Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ C
Phase 3 · Mercy Cancer Center - Cape Girardeau · Children's Oncology Group · NCT03067181 Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colore
Phase 3 · Mercy Cancer Center - Cape Girardeau · SWOG Cancer Research Network · NCT07018869 Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Phase 2 · Mercy Cancer Center - Cape Girardeau · SWOG Cancer Research Network · NCT05040360 Family Communications After Genetic Testing
NA · Mercy Cancer Center - Cape Girardeau · Alliance for Clinical Trials in Oncology · NCT07143487 Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, o
Phase 2 · Mercy Cancer Center - Cape Girardeau · National Cancer Institute (NCI) · NCT03739814 Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Phase N/A · Mercy Cancer Center - Cape Girardeau · SWOG Cancer Research Network · NCT04871542 APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patient
Phase 2 · Mercy Cancer Center - Cape Girardeau · National Cancer Institute (NCI) · NCT04858334 Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Phase 2 · Mercy Cancer Center - Cape Girardeau · Alliance for Clinical Trials in Oncology · NCT02523014

Look up another city

Look up another condition